 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) recommends sotrovimab
as an option for the treatment of patients with COVID-19 meeting specified clinical
criteria and subject to a commercial arrangement agreed with the company. The National
Health Service in England is legally required to make funding available for sotrovimab
in line with NICE’s recommendations.</p><p>The Government secured stocks of sotrovimab
on behalf of all nations in the United Kingdom. At current levels of use, driven by
the existing access policies, there is sufficient stock held to last until the latter
half of 2024. Discussions are ongoing with the manufacturer to ensure that stock is
available through normal commercial channels when this Government-owned stock is consumed.</p><p>Information
on the proportion of hospitals with accident and emergency units that have supplies
of Sotrovimab is not held.</p>
|
 |
